Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $15.5 million.

  • Relay Therapeutics' Share-based Compensation fell 3094.2% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.0 million, marking a year-over-year decrease of 3005.5%. This contributed to the annual value of $94.1 million for FY2024, which is 942.45% up from last year.
  • Per Relay Therapeutics' latest filing, its Share-based Compensation stood at $15.5 million for Q3 2025, which was down 3094.2% from $14.5 million recorded in Q2 2025.
  • Relay Therapeutics' Share-based Compensation's 5-year high stood at $27.2 million during Q1 2024, with a 5-year trough of $9.7 million in Q1 2021.
  • For the 5-year period, Relay Therapeutics' Share-based Compensation averaged around $17.6 million, with its median value being $16.1 million (2021).
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 56467.35% in 2021, then plummeted by 4596.0% in 2025.
  • Relay Therapeutics' Share-based Compensation (Quarter) stood at $10.2 million in 2021, then skyrocketed by 35.22% to $13.8 million in 2022, then soared by 39.44% to $19.3 million in 2023, then fell by 8.47% to $17.6 million in 2024, then fell by 11.95% to $15.5 million in 2025.
  • Its Share-based Compensation was $15.5 million in Q3 2025, compared to $14.5 million in Q2 2025 and $19.3 million in Q1 2025.